摘要
目的 探讨慢性粒细胞白血病(CML)合并恶性实体瘤患者的临床特点,并复习相关文献.方法 回顾性分析2006年8月至2018年8月郑州大学附属肿瘤医院、南阳市中心医院、河南科技大学第一附属医院、新乡市中心医院收治的8例明确诊断为CML且合并恶性实体瘤患者的资料,并结合文献对患者临床特征、治疗及预后进行总结.结果 8例患者中,男性3例,女性5例,中位年龄50岁(40~76岁).发病初7例患者CML处于慢性期,1例处于加速期;除1例仅给予羟基脲治疗外,其余7例均服用酪氨酸激酶抑制剂(TKI)治疗.8例患者中,同时性多原发癌(SMPC)2例,异时性多原发癌(HMPC)6例;手术治疗2例,手术+化疗1例,化疗4例,同位素治疗1例.1例SMPC患者已死亡,1例治疗中;6例HMPC患者均在继续治疗中.结论 CML与恶性实体瘤之间的关系目前暂无定论,发病少但并不罕见,临床医生应该提高认识,避免误诊和漏诊,治疗上应遵循综合治疗及个体化治疗两条主线.
Objective To explore the clinical features of chronic myelogenous leukemia (CML) combined with solid malignant neoplasms. Methods The clinical data of 8 CML patients with solid malignant neoplasms who were admitted to the Affiliated Tumor Hospital of Zhengzhou University, the Central Hospital of Nanyang City, the First Affiliated Hospital of Science and Technology University of Henan, and the Central Hospital of Xinxiang City from August 2006 to August 2018 were analyzed retrospectively. The clinical features, treatment and prognosis of the patients were summarized with the review of literature. Results Among the 8 patients, 3 were male and 5 female, aged 40-76 years, with a median of 50 years old. Seven cases were in CML chronic phase, and 1 was in accelerated phase. Seven patients were treated with tyrosine kinase inhibitor (TKI), and only 1 patient was treated with hydroxyurea. In 8 patients, two cases presented with synchronous multiple primary cancer (SMPC), 6 cases presented with heterochrony multiple primary cancer (HMPC). two patients received the operation, 1 patient received the operation and chemotherapy, 4 patients received chemotherapy, and 1 patient received the isotope treatment. One SMPC patient died and another one was under treatment, and 6 HMPC patients were under treatment. ConclusionsThe relationship between CML and solid malignant neoplasm is under discussion, but patients with CML and solid malignant neoplasm are not unusual. Clinicians should raise awareness to avoid misdiagnosis. The treatment should follow the two main lines that are comprehensive treatment and individualized treatment.
作者
汪小姣
米瑞华
陈琳
姚金晓
杨如玉
杨海平
尹俊杰
魏旭东
Wang Xiaojiao;Mi Ruihuar;Chen Lin;Yao Jinxiao;Yang Ruyu;Yang Haiping;Yin Junjie;Wei Xudong(Central Laboratory,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;Department of Hematology,the Affiliated Tumor Hospital of Zhengzhou Unirersity,Zhengzhou 450008,China;Department of Hematology,the Central Hospital of Nanyang City of Henan Province,Nanyang 473000,China;Department of Hematology,the First Affiliated Hospital of Science and Technology Unirersity of Henan,Luoyang 471000,China;Department of Hematology,the Central Hospital of Xinxiang City of Henan Province,Xinxiang 453000,China)
出处
《白血病．淋巴瘤》
CAS
2019年第2期96-99,共4页
Journal of Leukemia & Lymphoma
基金
河南省医学科技攻关计划省部共建项目(201701027).
关键词
白血病
髓样
慢性
肿瘤
多原发性
治疗
预后
leukemia, myelogenous, chronic
Neoplasms, multiple primary
Treatment
Prognosis
